Tositumomab: Difference between revisions
Jump to navigation
Jump to search
David Canner (talk | contribs) New page: ===Pharmacokinetics=== {| class="wikitable" border="1" width="52%" style="text-align:center" |- ! colspan="12" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmac... |
David Canner (talk | contribs) No edit summary |
||
| Line 52: | Line 52: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | |||
! Tositumomab | ! Tositumomab | ||
! Ofatumumab | ! Ofatumumab | ||
| Line 57: | Line 58: | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! Dosage (mg) | |||
! Tositumomab | ! Tositumomab | ||
! Ofatumumab | ! Ofatumumab | ||
! Rituximab | ! Rituximab | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |||
! Metabolism | |||
! Tositumomab | |||
! Ofatumumab | |||
! Rituximab | |||
! Ibritumomab | |||
|} | |||
|} | |} | ||
Revision as of 09:38, 6 December 2010
PharmacokineticsPharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| Tmax (hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| Cmax (ng/ml) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| Protein Binding (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| T1/2 (hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| AUC (ng/ml/hr) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| Clearance (L/h) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| Dosage (mg) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab | |||||||
|}